These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38360478)

  • 21. Vaccines for preventing herpes zoster in older adults.
    de Oliveira Gomes J; Gagliardi AM; Andriolo BN; Torloni MR; Andriolo RB; Puga MEDS; Canteiro Cruz E
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD008858. PubMed ID: 37781954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years.
    Lu PJ; O'Halloran A; Williams WW; Harpaz R
    Am J Prev Med; 2017 Mar; 52(3):362-372. PubMed ID: 27720342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of herpes zoster vaccination among Australian adults aged 65 and over.
    Ricks T; Trent MJ; MacIntyre CR
    Vaccine; 2022 Nov; 40(50):7182-7186. PubMed ID: 36336528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The clinical and epidemic characteristics of shingles (herpes zoster) and its prevention with vaccines].
    Afonina NM; Mikheeva IV
    Ter Arkh; 2013; 85(11):130-3. PubMed ID: 24432613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study.
    Baxter R; Bartlett J; Fireman B; Marks M; Hansen J; Lewis E; Aukes L; Chen Y; Klein NP; Saddier P
    Am J Epidemiol; 2018 Jan; 187(1):161-169. PubMed ID: 29309521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scarier than the flu shot? : The social determinants of shingles and influenza vaccinations among U.S. older adults.
    Vogelsang EM; Polonijo AN
    Vaccine; 2022 Nov; 40(47):6747-6755. PubMed ID: 36220715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Herpes zoster vaccine awareness and acceptance among adults in Saudi Arabia: a survey-based cross-sectional study.
    AlMuammar S; Albogmi A; Alzahrani M; Alsharef F; Aljohani R; Aljilani T
    Trop Dis Travel Med Vaccines; 2023 Oct; 9(1):17. PubMed ID: 37864275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
    Sanford M; Keating GM
    Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study.
    Amirthalingam G; Andrews N; Keel P; Mullett D; Correa A; de Lusignan S; Ramsay M
    Lancet Public Health; 2018 Feb; 3(2):e82-e90. PubMed ID: 29276017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15.
    Ward C; Byrne L; White JM; Amirthalingam G; Tiley K; Edelstein M
    Vaccine; 2017 Apr; 35(18):2372-2378. PubMed ID: 28363324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the herpes zoster vaccination programme on hospitalised and general practice consulted herpes zoster in the 5 years after its introduction in England: a population-based study.
    Andrews N; Stowe J; Kuyumdzhieva G; Sile B; Yonova I; de Lusignan S; Ramsay M; Amirthalingam G
    BMJ Open; 2020 Jul; 10(7):e037458. PubMed ID: 32641364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Routine Varicella Immunization on the Epidemiology and Immunogenicity of Varicella and Shingles.
    Otani N; Shima M; Yamamoto T; Okuno T
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35336994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer.
    Curran D; Patterson BJ; Carrico J; Salem A; La EM; Lorenc S; Hicks KA; Poston S; Carpenter CF
    Hum Vaccin Immunother; 2023 Dec; 19(1):2167907. PubMed ID: 36880669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A systematic literature review to assess the burden of herpes zoster disease in China.
    Yin D; Van Oorschot D; Jiang N; Marijam A; Saha D; Wu Z; Tang H; Diaz-Decaro J; Watson P; Xie X; Ren Y; He Y; Feng Y
    Expert Rev Anti Infect Ther; 2021 Feb; 19(2):165-179. PubMed ID: 32997550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.
    Lu PJ; Euler GL; Jumaan AO; Harpaz R
    Vaccine; 2009 Feb; 27(6):882-7. PubMed ID: 19071175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
    BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.